GALVmed receives aid to develop vaccine projects for Africa
GALVmed will receive $10 million in UK government aid to advance vaccine projects in Africa.
GALVmed will use the funds from the government's Department for International Development (DFID) to develop seven new vaccines for neglected tropical diseases.
The funding for GALVmed will enable the charity to focus on R&D work for combination vaccines, by addressing diseases affecting large ruminants, small ruminants and poultry.
This funding is part of joint funding with the Bill & Melinda Gates Foundation, who awarded GALVmed $40m earlier this year. The Gates Foundation and DFID are long-term backers of GALVmed.
GALVmed told Animal Pharm the seven vaccines supported by this latest funding include:
Small ruminant systemic multivalent vaccine;
Small ruminant reproductive multivalent vaccine;
Peste des petits ruminants-sheep and goat pox combination vaccine for Asia;
Contagious bovine pleuropneumonia -lumpy skin disease +/- Rift Valley fever combination vaccine;
Newcastle disease combination vaccine;
Peste des petits ruminants marker vaccine; and
African swine fever vaccine.
Edinburgh-based GALVmed will also be working on the Brucellosis Vaccine Prize and on a trypanosomosis program, which has separate funding.